Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Diabetes mellitus |
Dose: Subcutaneous – 0.5-1 unit/kg/day Note: Dose should be individualized and depends on patient's needs. Equipotent to regular human insulin when administered intravenous. Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin. Blood glucose monitoring is essential in all patients receiving insulin therapy. Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs. |
|
Indication: Diabetes mellitus Condition: Hepatic impairment |
Dose: Subcutaneous – Dose reduction may be needed Note: Dosage must be individualized; blood glucose monitoring is essential. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 1 Diabetes Mellitus Age: less than 4 years |
Dose: Subcutaneous Injection – Not established Note: Safety and efficacy not established |
|
Indication: Type 1 Diabetes Mellitus Age: 4-17 years Condition: during growth spurts |
Dose: Subcutaneous Injection – 0.8-1.2 units/kg/day Note: May require this dose during growth spurts |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Dose reduction may be needed Note: Dose reduction may be needed |
Administration
- Give within 15 minutes before meal
- Rotate injection sites
Side Effect
- Hypoglycaemia
- Injection site reactions
- lipodystrophy
- local and systemic hypersensitivity reactions
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Sermorelin
|
Decreased effect
|
|
Beta-blockers (Propranolol, Metoprolol, Atenolol, Bisoprolol, Carvedilol, Nadolol, Timolol, Sotalol)
|
Possible absence of hypoglycaemic warning symptoms
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypoglycemia
|
Severe low blood sugar risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Unopened Insulin Glulisine vials and cartridge systems should be stored in a refrigerator 2°C-8°C. Protect from light. Insulin Glulisine should not be stored in the freezer and it should not be allowed to freeze. Discard if it has been frozen. Unopened vials/cartridge systems not stored in a refrigerator must be used within 28 days.
Opened vials, whether or not refrigerated, must be used within 28 days. If refrigeration is not possible, the open vial in use can be kept unrefrigerated for up to 28 days away from direct heat and light, as long as the temperature is not greater than 25°C.
Opened vials, whether or not refrigerated, must be used within 28 days. If refrigeration is not possible, the open vial in use can be kept unrefrigerated for up to 28 days away from direct heat and light, as long as the temperature is not greater than 25°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.